Nimbus is applying deep structure-based drug discovery expertise to create novel small molecules for substantial and underserved human diseases in metabolism, oncology and immunology. The company’s targets include emerging and well-validated targets that have proven intractable to others in the pharmaceutical and biotechnology industry, and its success has been reflected in the company’s high-profile partnerships with Gilead, Celgene, and Genentech.
| Headquarters | Cambridge, MA |
| Website | www.nimbustx.com |
| Pipeline | Preclinical & Clinical Programs |
| Partners | Celgene, Genentech, Gilead, Monsanto, Schrödinger |
| @NimbusTx |